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(a) Morphotypes of Candida albicans (blue sector, vegetative forms; pink sector, forms related to mating or changes in ploidy).
Cell types shown include: budding yeast cells; elongated conjoined yeasts forming pseudohyphae; parallel-sided hyphae;
chlamydospores formed from suspensor cells; enlarged goliath cells formed under zinc deprivation (unpublished study,
image from Duncan Wilson); intestinal gut form cells (image from Suzanne Noble); mating competence defined by white–
grey–opaque cell transitions (images from Guanghua Huang); elongated chemotactic shmoo-mating projections leading to
tetraploid zygote formation (images from David Soll and Karla Daniels); trimera formed by unequal chromosome segregation
under antifungal exposure (image from Judith Berman). (b) Superficial yeast colonization and invasion of the chicken
chorioallantoic membrane by C. albicans hyphal cells.
Abstract
Candida albicans is normally a harmless commensal of human beings, but it can cause superficial infections of the mucosa
(oral/vaginal thrush) in healthy individuals and (rarely) infections of the skin or nails. It can also become invasive, causing
life-threatening systemic and bloodstream infections in immunocompromised hosts, where the mortality rate can be as high
as 50%. It is the most common cause of serious fungal infection and is a common cause of nosocomial infections in
hospitals. Some strains have been recognized that are resistant to azoles or echinocandins, which are the first-line
antifungals for treatment of C. albicans infections.
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TAXONOMY
First description in 1839 by Langenbeck. Candida – Latin
candidus, meaning ‘gleaming white’; albicans – Latin albi-
care, meaning ‘to whiten’, suggestive of the white exudate
on the infected mucosal surfaces.
Superkingdom Eukaryote, kingdom Fungi, subkingdom
Dikarya, phylum Ascomycota, subphylum Saccharomyco-
tina, class Saccharomycetes, subclass Saccharomycetidae,
order Saccharomycetales, family Metschnikowiaceae, genus
Candida, species albicans.
PROPERTIES
C. albicans is highly polymorphic (see the graphical
abstract), switching in vivo to alternative vegetative growth
forms in response to changing environmental conditions
such as nutrient availability, temperature, pH, CO2 and the
presence of serum [1]. This phenotypic flexibility is an
important virulence factor that aids in its invasion of epithe-
lia, dissemination throughout the host and survival in dif-
ferent host niches, and also helps to modulate the host
immune response and counteract immune surveillance. It is
highly metabolically flexible and can utilize different nutri-
ent sources simultaneously through post-transcriptional
rewiring and constitutive expression of alternative metabolic
pathways [2].
GENOME AND EVOLUTION
C. albicans was one of the first eukaryotic pathogens to have
its genome sequenced [3]. Clinical isolates have a 16Mb
genome, with 33.3% GC content, 132 non-coding RNAs, a
number of transposons, 8 diploid chromosomes and 6735
(haploid) ORFs. The C. albicans genome is highly plastic
and high levels of heterozygosity, intra-chromosome recom-
bination and aneuploidy can be observed between genomes
of different strains. The loss of heterozygosity, chromosomal
rearrangements and whole chromosome or segmental aneu-
ploidies lead to stress adaptation and can also affect drug
sensitivity by influencing the copy number of key drug-
resistance alleles [4]. Many key virulence-associated func-
tions are performed by multi-gene families, some of which
have evolved by sub-telomeric gene duplication and
expansion.
Even though haploid forms of C. albicans have been identi-
fied [5], and fusion of opposite mating types has been
observed [6], no full meiotic sexual cycle has been discov-
ered. The populations observed in a single host are mostly
clonal in nature. Under stressful environmental conditions
it has been shown to undergo a parasexual cycle where two
diploids of opposite mating types fuse to form tetraploid
zygotes that undergo concerted chromosome loss to give
rise to near diploids.
PHYLOGENY
C. albicans belongs to a limited CTG clade of asexual Can-
dida species in the Saccharomycetales order, which decode
the codon CTG as Ser instead of Leu [7], resulting in practi-
cal difficulties in expressing heterologous gene sequences.
Whole-genome sequence analysis and comparisons with
other Candida species of the CTG clade have shown the
expansion of many gene families, conferring pathogenicity,
by gene duplication in C. albicans which makes it the most
pathogenic of the Candida species. The closest relative is
Candida dubliniensis, although there is no correlation
between phylogeny and relative virulence. Some other path-
ogenic Candida species are haploid.
KEY FEATURES AND DISCOVERIES
C. albicans lives asymptomatically as a commensal of
warm-blooded animals. No environmental reservoirs are
known. It is transmitted from mothers to neonates and by
nosocomial infection. Between 30–70%healthy individuals
carry at least one Candida species commensally. However, it
causes life-threatening and fatal bloodstream and invasive
systemic infections in immunocompromised individuals
and upon breaching of protective mucosal barriers during
trauma and surgical interventions. This is also promoted
when the suppressive host microbiota is inhibited [8].
During the course of infection, C. albicans can manipulate
the host immune response by altering its cell-wall compo-
nents, changing cell shape and secreting various virulence
factors. Its cell wall is a bilaminate structure composed of
outer fibrillar mannoproteins and an inner core of b-glu-
cans and chitin that all contribute to the immune response.
Changes in the structure and composition of the wall occur
in different host microenvironments and in response to the
action of antifungal drugs. This can prevent or interfere
with phagocytosis and inhibit or modulate the protective
Th1, Th17 and inflammasome immune responses, and acti-
vate the anti-inflammatory Th2 response, leading to toler-
ance [9]. Phagocytosed yeasts can form hyphae and induce
pyroptosis (a form of apoptosis caused by NLRP3 inflam-
masome activation). Even if phagocytosed, it has the ability
to induce its own non-lytic expulsion and prevent acidifica-
tion and maturation of the phagolysosomes of macro-
phages, and to express detoxifying enzymes to counteract
ROS/RNS-induced damage in the phagosome.
It expresses invasins that induce its uptake by epithelial
cells, and adhesins that confer the ability to adhere to several
biotic and abiotic surfaces (such as medical implants and
catheters), and forms drug-resistant biofilms. It also secretes
several hydrolytic enzymes (e.g. proteases and lipases), zinc-
scavenging proteins and a pore-forming toxin called candi-
dalysin [10], which aids tissue penetration and results in
damage of host epithelia and activation of immune
responses.
C. albicans can inhibit host complement activation, inacti-
vate antimicrobial peptides and inhibit other immune cell
functions, thus weakening host defences. Antifungal drugs
targeting cell-wall b-1,3 glucan (echinocandins) or the
ergosterol biosynthesis pathway (azoles) are used as first-line
options to treat infection, but C. albicans can develop
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resistance via the upregulation of azole efflux pumps, the
acquisition of mutations affecting the structure or expression
of the azole target CYP51 (cytochrome P450 lanosterol 14a-
demethylase), or the induction of compensatory changes in
chitin in the cell wall in response to echinocandins.
OPEN QUESTIONS
. An in-depth understanding of the determinants of
pathogenicity, adaptability and fitness of C. albicans
needs to be developed.
. The roles of many of the cell-wall proteins and other
surface components in the immune response and in
disease are not fully understood.
. Studies of the variability in individual host responses
and the influence of human genetic polymorphisms in
determining the outcome of Candida infections is
generating opportunities to design personalized
therapeutic options.
. Diagnostics that distinguish commensal carriage and
invasive disease are needed. High mortality is often
associated with failure to make an early and accurate
diagnosis.
. Research towards developing an anti-Candida vaccine is
urgently required.
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